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Melanoma Cell Signalling:  
Looking Beyond RAS-RAF-MEK 




Melanoma is an invasive and malignant form of skin cancer (Besaratinia and Pfeifer, 2008). 
It originates from melanocytes, which reside in the epidermal layer of the skin.  Besides the 
skin, melanoma’s rapidly proliferative and aggressive nature leads to its manifestation in 
internal organs such as brain, lung and liver (Franco-Lie et al., 2011; Lejeune et al., 1992). 
Ultraviolet (UV) radiation (sunlight or tanning beds) is the main carcinogen involved in 
melanoma development. However, the type (UVA versus UVB) and duration of UV 
radiation (intermittent versus chronic and childhood sun exposure) necessary for melanoma 
initiation remains ambiguous (Algazi et al., 2010; Besaratinia and Pfeifer, 2008; Lazovich et 
al., 2010; Walker, 2008). In addition, the presence of melanocytic nevi and hereditary genetic 
mutations predisposes individuals to melanoma (Navarini et al., 2010; Pho and Leachman, 
2010; Whiteman et al., 2003). As a result of these factors, it is estimated that 132,000 
melanoma skin cancers occur annually (World Health Organization [WHO], 2011). This 
value is set to rise by 4,500 incidences for every 10% decrease in the UV-protective ozone 
levels (WHO, 2011).  
Prevention strategies designed to curtail the onset of melanoma and improved treatment for 
this evolving anomaly require urgent action. Current treatments and adjuvant therapies for 
melanoma includes, surgical excision, radio-, chemo- and immunotherapy (Dummer et al., 
2010; Petrescu et al., 2010). However, with the recurrence of these melanomas, the spotlight 
is on molecular targeted therapy. Such therapies require an in depth knowledge of 
melanoma signalling to treat this cancer. Molecular targeted therapy has focused 
predominantly on the RAS-RAF-MEK [mitogen activated protein kinase  
(MAPK)-extracellular signal-regulated kinase (ERK) kinase] and phosphoinositide-3-kinase 
(PI3K)/AKT pathways (Algazi et al., 2010; Friedlander and Hodi, 2010; Held et al., 2011; 
Sullivan and Atkins, 2010). However, due to the complex network of signalling pathways, it 
has become evident that targeting single pathways to eradicate melanoma is insufficient 
(Table 1) (Jiang et al., 2011; Johannessen et al., 2010; Nazarian et al., 2010; Shields et al., 
2007). Shields et al. (2007) found a distinct subset of melanoma cell lines that did not exhibit 
high ERK and AKT activation but had increased expression of epithelial markers like  
P-cadherin, E-cadherin and CD24. These epithelial-like melanoma also had a loss of p53 
function, decreased microphthalmia-associated transcription factor (MITF) levels and its 
targeted gene expression. Recent studies have also shown that many subsets of melanoma 
cells exhibit resistance to B-RAF inhibitors (Jiang et al., 2011; Nazarian et al., 2010). 
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(Shields et al., 2007) 
C-RAF/MEK/ERK signalling B-RAF inhibition (Nazarian et al., 2010) 
Impaired FOXO3a nuclear localisation 
result in reduced Bim expression 
MEK1/2 
inhibition  
(Yang et al., 2010) 
P13K/AKT signalling B-RAF inhibition (Jiang et al., 2011) 
Amplified wild-type KIT/CDK4 
signalling 
B-RAF inhibition (Smalley et al., 2008) 
Platelet-derived growth factor receptor 
ǃ (PDGFRǃ) signalling B-RAF inhibition (Nazarian et al., 2010) 
COT/MEK/ERK signalling B-RAF inhibition (Johannessen et al., 2010) 
Melanoma subgroups with constitutive 
B-RAF and MEK activity 
N-RAS inhibition (Inamdar et al., 2010) 
Table 1. Signalling pathways/molecules rendering melanoma resistance. 
Melanoma resistance to chemotherapy can and has been attributed to changes in cell 
signalling events (Grossman and Altieri, 2001). Photodynamic therapy (PDT) and cytotoxic 
agents were found to enhance survivin (member of the inhibitor of apoptotic protein family) 
expression which desensitised these cells to apoptosis (Ferrario et al., 2007; Qiu et al., 2005). 
Other anti-apoptotic factors (e.g. Bcl-2, and Bcl-XL) are also found to be highly expressed in 
melanoma resulting in a chemo-resistant phenotype (Grossman and Altieri, 2001; Rass and 
Hassel, 2009). Multi-drug resistance transporters and DNA repair mechanisms that prevent 
cytotoxicity induced by alkylating agents have also been implicated in chemo-resistance 
(Grossman and Altieri, 2001; Rass and Hassel, 2009). As such, it is imperative to address 
possibilities of other mutations and compensatory/alternative signalling pathways involved 
in melanoma development and persistence. Therefore, this review presents an overview of 
melanoma cell signal transduction and highlights the recent advances made in this field as 
well as identifying molecular targets with therapeutic potential. 
2. Melanoma signalling and therapeutical targets 
2.1 Common therapeutical targets 
Common oncogenic mutations in melanoma have been selected for targeted therapy. 
Inhibitors to these mutant proteins or their downstream effectors are currently undergoing 
clinical evaluation. However, it has been reported that melanoma cells are able to acquire 
resistance to some of these drugs (Jiang et al., 2011; Nazarian et al., 2010; Paraiso et al., 2011). 
2.1.1 KIT 
KIT, a receptor tyrosine kinase (RTK), is involved in normal melanocyte signalling (Easty et 
al., 2011). It is necessary for the migration of melanocytic precursors from the neural crest 
and regulates the survival, development and homeostasis of melanocytes (Hou et al., 2000; 
Wehrle-Haller, 2003). KIT undergoes genetic alterations in chronically sun damaged, acral 
and mucosal melanoma subgroups (Curtin et al., 2006; Friedlander and Hodi, 2010). Some 
melanomas also possess amplified wild type (WT) KIT due to high copy number (Curtin et 
al., 2006). Its increased expression has also been observed in melanoma cells without 
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aberrant gene amplification (Curtin et al., 2006). A gain-of-function mutation or increased 
kinase activity of KIT causes constitutive activity of the MAPK and PI3K pathways which 
may lead to a hyper-proliferative and invasive melanoma subgroup (Woodman and Davies, 
2010). Therefore, it has been postulated that targeting the KIT receptor may reduce the 
incidence of melanoma.  
Imatinib (RTK inhibitor) prevents autophosphorylation of KIT which leads to the 
inactivation of MAPK, JAK-STAT, PI3K/AKT and anti-apoptotic pathways (Heinrich et al., 
2000; Jiang et al., 2008). Imatinib was shown to reduce proliferation in KIT mutant mucosal 
melanoma cell cultures (Jiang et al., 2008). Although, this inhibitor was ineffective in 
unamplified WT KIT melanoma, it is unclear if it can eradicate those tumours which 
overexpress this receptor. Smalley et al. (2008) found that imatinib treatment was only 
effective in those melanomas which had elevated levels of phosphorylated (phospho) KIT. 
This suggests that irrespective of its overexpression, the efficacy of imatinib in treating 
melanoma requires the presence of active KIT. This inhibitor has specificity towards certain 
KIT mutation. While it is effective against mutant KIT in the juxtamembrane domain, it is 
ineffective against mutations occurring in the kinase domain of these receptors. In support, 
V559A (juxtamembrane domain) mutated KIT in a metastatic lung melanoma patient 
responded to imatinib therapy (Terheyden et al., 2010). However, imatinib had no effect in 
D820Y (kinase domain) mutated KIT in SM3 melanoma cells but another RTK inhibitor, 
sunitinib, inhibited the proliferation of these cells (Ashida et al., 2009).  
Some tumours have evolved imatinib resistance by creating secondary genetic mutations in 
KIT but their occurrence in melanoma is unknown (Lim et al., 2008). A genetic comparison 
between imatinib-naïve and resistant melanoma cells will be useful to identify secondary 
mutations generated in resistant cell lines. Mutations can occur in the extracellular, 
juxtamembane and kinase domains of the KIT receptor (Woodman and Davies, 2010). Double 
KIT mutations have been reported in those melanomas which marginally responded to 
imatinib treatment (Curtin et al., 2005; McDonnell et al., 2011; Torres-Cabala et al., 2009). Three 
indolinone compounds were found to inhibit proliferation, and induce cell cycle arrest and 
apoptosis in mast cells harbouring KIT juxtamembrane and kinase domain mutations (Liao et 
al., 2002). Other RTK inhibitors, like nilotinib and dasatinib are effective against certain multi-
exon KIT mutations except for those occurring at exon 14 (T670I) (Garrido and Bastian, 2010; 
Schittenhelm et al., 2006). Collectively, little is known about the effectiveness of different 
inhibitors on patients with specific KIT mutations. Since these inhibitors do not target all 
mutants, a matrix of various inhibitors and their efficacy against different KIT aberrations will 
aid in patient selection. The weight of evidence also suggests that patient selection for KIT 
inhibition therapy should not solely rely on the overexpression and mutational status of this 
receptor (Hofmann et al., 2009; Smalley et al., 2008). It is also necessary to identify constitutive 
KIT activation (phosphorylated form) and their involvement in melanoma progression before 
administration of RTK inhibitor therapy. This information is necessary, before an evaluation of 
KIT as a viable therapeutic target in melanoma patients is possible. 
2.1.2 N-RAS 
N-RAS, a GTPase of the RAS family activates RAF proteins in the MAPK signalling cascade 
and is involved in regulating cellular homeostasis and stress response (Held et al., 2011; 
Whitwam et al., 2007). Of the RAS isoforms (K-RAS and H-RAS), N-RAS is frequently mutated 
at codon 61 in 15-20% of melanomas (Held et al., 2011; Karnoub and Weinberg, 2008; Platz et 
al., 2008; Whitwam et al., 2007). N-RAS mutations increased as the cancer progressed from 
www.intechopen.com
 
Skin Cancers – Risk Factors, Prevention and Therapy 
 
90
radial to vertical growth phase suggesting that these mutations are involved in both melanoma 
development and progression (Demunter et al., 2001; Omholt et al., 2003; Rosso et al., 2009). 
The mutant N-RAS exists in a GTP-bound conformation due to its defective GTPase activity 
which prevents the hydrolysis of GTP to GDP (Karnoub and Weinberg, 2008). This 
constitutive activity induces persistent activation of the MAPK and PI3K pathways resulting in 
melanoma cell survival and proliferation (Jiang et al., 2011; Sullivan and Atkins, 2010). 
Eskandarpour et al. (2009) found that mutant N-RAS is also necessary for the invasive and 
migratory phenotypes of melanoma cells. Also the overexpression of RAS has been implicated 
in melanoma chemoresistance to cytotoxic agents (Fujita et al., 1999).  
RAS undergoes post-translational modifications to facilitate its association to the plasma 
membrane which is necessary for its bioactivity (Nammi and Lodagala, 2000; Sebti and 
Hamilton, 1997). A crucial modification is the farnesylation at its carboxy-terminus 
catalysed by farnesyl tranferase (Nammi and Lodagala, 2000; Reiss et al., 1990; Sebti and 
Hamilton, 1997). N-RAS is deactivated by farnesyl transferase inhibitors (FTI) which reduce 
its oncogenic potential making it a viable target for melanoma therapy (Johnston, 2001; 
Smalley and Eisen, 2003). However, early studies found that BZA-5B (FTI) increased 
resistance to cisplatin (cytotoxic drug) treatment in 224 melanoma cells (Fokstuen et al., 
1997). In contrast, Niessner et al. (2011) found that SCH66336 (Lonafarnib; FTI) together with 
sorafenib showed efficacy in inducing growth inhibition and apoptosis of melanoma cells 
through mammalian target of rapamycin (mTOR) signalling however, no changes to the 
upstream effector, AKT was observed. They found that the FTI did not affect RAS activity 
but inhibited another GTPase, RHEB, which affected the mTOR signalling pathway. 
Smalley et al. (2003) found that SCH66336 increased melanoma chemosensitivity to cisplatin-
mediated cytotoxicity through G2/M-phase cell cycle arrest. Interestingly, this was not 
coordinated by typical RAS-driven ERK or P13K pathways. SCH66336 alone caused G1-
phase cell cycle arrest and retinoblastoma inactivation in human (Colo 853) and mouse (B16) 
melanoma cells resulting in low proliferation and high apoptosis levels (Smalley and Eisen, 
2003). In this study, RAS activity post-FTI treatment was not observed. Therefore, it is not 
clear if SCH66336-induced cytotoxicity is a result of RAS inactivity or the inhibition of other 
farnesylated proteins. It has also been reported that the RAS mutational status did not 
correlate with their sensitivity to FTI which suggests that other signalling molecules are 
affected by these inhibitors (Niessner et al., 2011; Sebti and Hamilton, 1997; Sepp-Lorenzino 
et al., 1995). Although, FTI are beneficial in joint therapies to overcome drug resistance, its 
non-specificity to N-RAS needs to be addressed (Flaherty, 2006; Held et al., 2011; McCubrey 
et al., 2009). Furthermore, FTI may also be ineffective if RAS downstream targets acquire 
oncogenic mutations.  
2.1.3 B-RAF 
B-RAF is a serine threonine kinase and together with C-RAF and A-RAF belong to the RAF 
kinase family. In the MAPK cascade, B-RAF phosphorylates MEK which results in the 
activation of the ERK pathway. B-RAF mutations are prevalent in 50-60% of melanomas 
with the most common mutation occurring at the 600th amino acid (valine to glutamate) 
(Held et al., 2011; Inamdar et al., 2010). It predominantly occurs in cutaneous melanomas at 
sites damaged by intermittent UV exposure (Bauer et al., 2011; Puzanov and Flaherty, 2010). 
Mutant B-RAF is constitutively active and independent of RAS activation (Inamdar et al., 
2010). Persistent B-RAF activation leads to ERK-induced melanoma survival, proliferation, 
angiogenesis and invasion (Inamdar et al., 2010). Therefore, the B-RAF protein has become a 
promising candidate for molecular targeted therapy.  
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The general inhibitor, Sorafenib binds to the inactive forms of B-RAF and thus, is more 
effective in blocking WT B-RAF then constitutively active mutant B-RAF (McCubrey et al., 
2009). In contrast, PLX4720 binds to both the inactive and active forms while SB590885 only 
associates with active B-RAF (McCubrey et al., 2009). PLX 4720 specifically inhibits B-RAF 
(V600E) mutant in melanoma cells and enhances Bims (pro-apoptotic protein) levels to 
induce apoptosis (Jiang et al., 2010). Another mutant B-RAF specific inhibitor, PLX4032 
sensitised melanoma cells to ionizing radiation which induced cell cycle arrest, inhibited 
colony formation and invasion (Sambade et al., 2011). Although, RAF inhibitors seem 
promising in combating melanoma growth, this therapy has met with ‘roadblocks’ due to 
the emergence of alternative signalling pathways in these cells. PLX4032 reduced tumours 
in melanoma patients but drug resistance occurred after the initial anti-tumour response 
(Nazarian et al., 2010). This was due to reactivation of C-RAF/MEK/ERK by N-RAS 
mutations and upregulation of the PDGFRǃ-dependent survival pathways. Jiang et al. (2011) 
found that melanoma cells resistant to PLX4720 maintained high ERK levels but low MEK 
activity. MEK inhibition itself was shown to be ineffective in overcoming PLX4720 resistance 
but serum starvation, PI3K/AKT and ERK inactivation reduced melanoma cell viability. 
Another route of resistance evident in melanoma patients relapsing from RAF or MEK 
inhibition therapy was that of COT-mediated ERK activation which was independent of 
RAS/RAF signalling (Johannessen et al., 2010).  
ATP-competitive RAF inhibitors were found to inhibit ERK activation in B-RAF mutant cells 
but increased the proliferation of cells in RAS/RAF WT tumours (Hatzivassiliou et al., 2010). 
This could be due to the induction of WT B-RAF/C-RAF homo- or heterodimers after 
inhibitor treatment which allows signalling to continue via the uninhibited subunit of the 
dimer (Hatzivassiliou et al., 2010; Poulikakos et al., 2010). It is suggested that by increasing 
RAF inhibitor concentrations, both subunits of the dimer can be inactivated negating 
downstream signalling (Poulikakos et al., 2010). In addition, protein kinase D3 blockade in 
conjunction with RAF or MEK inhibition can prevent the reactivation of the MAPK pathway 
and thereby decrease the survival of resistant melanoma cell lines (Chen et al., 2011). On the 
whole, further research is needed to determine other modes of overcoming RAF inhibitor 
resistance. This also highlights the necessity to target downstream effectors of B-RAF/N-
RAS and other compensatory survival pathways in melanoma.  
2.1.4 Phosphoinositide-3-kinase/AKT 
The PI3K/AKT pathway is activated by N-RAS and/or RTK which directs cell growth, 
proliferation, differentiation and survival (Held et al., 2011; Sullivan and Atkins, 2010). 
There are three classes of P13K and this dictates their substrate specificity (Aziz et al., 2009). 
P13K has several downstream targets such as AKT, mTOR, FOXO and nuclear factor-κB 
(NFκB) (Held et al., 2011). Phosphatase and tensin homolog (PTEN) dephosphorylates 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) thus preventing AKT activation and 
blocking PI3K signalling. As a result of mutant N-RAS, PTEN depletion/inactivation 
and/or constitutive activation of receptors, the PI3K pathway is permanently activated 
leading to malignant transformation of melanocytes (Held et al., 2011). Constitutive PI3K 
activity was associated with radiation resistant melanoma cells as treatment with LY294002 
(PI3K inhibitor) sensitised melanoma cells to radiation and apoptosis (Krasilnikov et al., 
1999). PI3K-dependent matrix metalloproteinase expression has also been implicated in 
vasculogenic mimicry in highly aggressive melanomas (Hess et al., 2003). 
In melanoma therapy, besides PI3K, AKT and mTOR are also potential targets because of 
their involvement in tumorigenesis (Ko and Fisher, 2011; Sullivan and Atkins, 2010). 
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Govindarajan et al. (2007) showed that AKT overexpressing WM35 melanoma cells had high 
levels of vascular endothelial growth factor (VEGF; pro-angiogenic) and reactive oxygen 
species (ROS) in vitro and when implanted into nude mice, generated highly invasive and 
angiogenic tumours in vivo. Although, AKT overexpression and mutations have been 
reported, it is the activity of phospho-AKT that drives melanoma development (Stahl et al., 
2004; Sullivan and Atkins, 2010). Approximately, 43-60% of those melanomas examined, had 
deregulated AKT signalling (Stahl et al., 2004). In a phase two study, using everolimus 
(mTOR inhibitor) and bevacizumab (angiogenic inhibitor), 53% of the melanoma patients 
had reduced tumour measurements, 12% of which were significant (Hainsworth et al., 
2010). However, it was found that the RAD001 (mTOR inhibitor) induced a PI3K-dependent 
feedback loop activating the ERK pathway in some human cancers (Carracedo et al., 2008). 
Therefore, it is critical that the dual inhibition of the MAPK and PI3K pathways be used in 
treating these melanomas.  
PI-103, a dual PI3K/mTOR inhibitor promoted in vivo tumour growth via inhibiting 
apoptosis and immunosurveillance in FVB/N WT mice transplanted with 37-31E-F3 
melanoma cells (Lopez-Fauqued et al., 2010). In these mice, the combination of sorafenib  
(B-RAF inhibitor) and PI-103 increased the tumour volume compared to that seen for 
sorafenib alone (Lopez-Fauqued et al., 2010). Unlike the immunocompetent FVB/N WT 
mice, PI-103 was effective in reducing tumour growth in immunocompromised BALB/c 
nude mice. This data suggests that the immune status of the mouse models can also affect 
efficacy of PI-103 treatment. Although, the outcomes of this study could be specific to the 
type of melanoma cells, mouse models and PI3K inhibitor that were used, there is the 
possibility of risks associated with treating patients with different immune profiles or 
melanoma patients under immunotherapy in combination with signal transduction 
inhibition [for more information see Shada et al. (2010)]. Some of these PI3K/AKT/mTOR 
inhibitors are still undergoing clinical trials (Ko and Fisher, 2011; Sullivan and Atkins, 2010). 
2.2 New therapeutical targets 
In this section, potential signalling molecules and lesser known therapeutical targets 
undergoing clinical trials are discussed (Figure 1). The inhibition of these targets may help 
overcome drug resistance in melanoma (Hatzivassiliou et al., 2010; Jiang et al., 2011; 
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2.2.1 Aryl hydrocarbon receptor  
Aryl hydrocarbon receptors (AhR) are cytosolic transcription factors which are triggered in 
response to environmental toxicants (e.g. dioxins and polychlorinated biphenyls) (Schmidt 
and Bradfield, 1996). After ligand binding, the AhR complex translocates into the nucleus 
where it dimerises with the AhR nuclear translocator while its co-factors [e.g. heat shock 
protein 90 (Hsp90)] dissociate to initiate transcription of target genes. It can also be activated 
independent of ligand binding but the mode of action is not clear (Schmidt and Bradfield, 
1996). In the skin, UV radiation produces 6-formylindolo[3,2-b]carbazole (FICZ), an AhR 
ligand derived from tryptophan which can stimulate this pathway in response to stress 
(Fritsche et al., 2007). Fritsche et al. (2007) found that AhR-knockdown HaCaT keratinocytes 
do not possess phosoho-ERK1/2 activity due to inhibition of EGFR internalisation, which 
suggested that AhR is also involved in EGFR activation in these cells. It is unclear if the 
same occurs in melanocytes but the high levels of phospho-ERK in melanoma cells suggest a 
role for Ah receptors.  
Environmental toxins can initiate melanogenesis by triggering the AhR signalling pathway 
in melanocytes (Jux et al., 2011; Luecke et al., 2010). Luecke et al. (2010) showed that 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), activated the AhR signalling pathway and induced 
tyrosinase activity, which correlated with an increase in melanin content in melanocytes. 
They also found that UVB radiation induced AhR-dependent pigmentation albeit weaker 
than that stimulated by TCDD. Since AhR-deficient mice displayed pigmented skin and fur, 
this transcription factor was not necessary for constitutive melanogenesis but is involved in 
eliciting responses initiated by exogenous stimuli (Luecke et al., 2010). In accordance, Jux et 
al. (2011) found that AhR expressed in normal murine melanocytes were involved in both 
cell proliferation and UV-induced skin pigmentation. Moreover, AhR-deficient melanocytes 
expressed low levels of c-KIT (overexpressed in some melanoma tumours) than WT 
melanocytes. On the whole, there is evidence to suggest that melanocytes express functional 
AhR which can be activated by UV radiation (Jux et al., 2011; Luecke et al., 2010).  
Melanoma cells express AhR mRNA which corresponds to its intracellular protein content 
(Villano et al., 2006). Interestingly, these levels corresponded to increasing invasiveness of 
melanoma cells but were lower than that seen in melanocytes. In the highly invasive A2058 
melanoma cells, the expression of AhR target genes, CYP1A1 and CYP1B1 was increased by 
TCDD which is a known stimulator of this signalling pathway (Villano et al., 2006). The use 
of AhR antagonist abrogated CYP1 expression in A2058 cells which suggests that this 
signalling pathway is functional in these tumour cells. Furthermore, TCDD-dependent 
increase in matrix metalloproteinase expression was found to aid in the metastasis of A2058 
melanoma cells (Villano et al., 2006). In addition, Roman et al. (2009) found that both tumour 
volume and vasculature were decreased when B16F10 melanoma cells were transplanted 
onto AhR-/- mice, compared to AhR+/+ mice. This decrease in angiogenesis was mediated by 
the downregulation of hypoxia-inducible factor-1ǂ (HIF-1ǂ)-dependent VEGF expression. 
As UV radiation can activate the AhR pathway in melanoma, it is conceivable that 
hyperactivation of this pathway can direct angiogenesis and metastasis of these cells (Jux et 
al., 2011; Kramer et al., 2005; Villano et al., 2006). Currently, further investigation is required 
to further our understanding of the AhR signalling pathway in melanoma.  
2.2.2 Heat shock protein 90 
B-RAF, N-RAS, C-RAF and p53 are some of the client proteins of Hsp90 (Heath et al., 2011; 
Mehta et al., 2011). Hsp90 is involved in maintaining the conformation, stability and cellular 
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localisation of its client proteins (Powers and Workman, 2006). It also acts as a molecular 
chaperone for proteins involved in invasion/metastasis, angiogenesis and survival (Powers 
and Workman, 2006). Conjunctival melanoma tissues expressed higher levels of Hsp90 than 
did nevi (Westekemper et al., 2011). More importantly, those tumours which recurred 
locally had increased Hsp90 levels compared to recurrence-free conjunctival melanoma 
tumours. This suggests that Hsp90 plays a role in the metastatic progression of melanoma. 
Hsp90 inhibition correlated with modulations to the phospholipid metabolism and growth 
arrest induced by 17-AAG (Hsp90 inhibitor) in SKMEL28 and CHL-1 melanoma cells  
(Beloueche-Babari et al., 2010). In hypoxic melanoma tumours, Hsp90 was implicated in  
Bcl-2-dependent stabilisation of HIF-1ǂ, which was found to regulate VEGF and promote 
tumour angiogenesis. Thus, the inhibition of Hsp90 will destabilise HIF-1ǂ and may reduce 
the vascularisation of melanoma tumours. Since Hsp90 interacts with several oncognenic 
proteins involved in melanoma, disrupting their interaction may reduce the stability of these 
pro-tumour proteins (Powers and Workman, 2006).  
In melanoma and breast cancer cells, survivin induced PDT resistance (Ferrario et al., 2007). 
PDT increased survivin expression and phosphorylation both in vitro (BA mouse breast 
cancer cells) and in vivo (C3H mice transplanted with BA cells). Treatment with 17-AAG and 
PDT reduced both phospho-survivin and –AKT levels. Additionally, there was an increase 
in poly (ADP-ribose) polymerase cleavage and Bcl-2 protein degradation which resulted in 
BT-474 (human breast cancer) cell death post-17-AAG/PD therapy. Likewise, in 
YUSAC2/T34A-C4 melanoma cells, forced expression of phospho-survivin led to reduced 
apoptosis after PDT treatment, while the reverse occurred when dominant-negative 
survivin was expressed. Qiu et al. (2005) also found that survivin desensitised melanoma 
cells to betulinic acid-induced cytotoxicity. Betulinic acid caused an increase in EGFR 
activation, phospho-ERK, phospho-AKT and survivin levels in melanoma cells. The 
blockade of EGFR caused a decrease in both AKT and survivin expression which resulted in 
cell death. Therefore, high ERK/AKT activity in combination with increased survivin levels 
lead to melanoma cell survival (Ferrario et al., 2007; Qiu et al., 2005). Since, both survivin 
and AKT are Hsp90 client proteins and have been implicated in PDT- and chemo-resistant 
melanoma cells, targeting Hsp90 may have beneficial effects (Qiu et al., 2005).  
Mehta et al. (2011) found that Hsp90 inhibitors suppressed proliferation, colony formation 
and transformation of melanoma cells irrespective of their B-RAF mutational status. 
However, Hsp90 inhibitors (PF-4470296 and PF-3823863) degraded mutant but not WT B-
RAF protein and reduced the activation of MEK/ERK in B-RAF mutant A2058 melanoma 
cells (Mehta et al., 2011). These inhibitors also induced the degradation of C-RAF, AKT, 
ErbB2 and cMET (involved in tumour progression) in both mutant (A2058) and WT 
(MeWo) BRAF melanoma cell lines. In in vivo studies, PF-3823863 induced tumour growth 
inhibition in both A2058 and MeWo melanoma xenografts. Although, PF-4470296 and PF-
3823863 are effective in treating both WT and mutant B-RAF melanomas, the mechanism 
involved seems to be different; unlike mutant B-RAF, WT B-RAF is not depleted but other 
oncogenic client proteins responsible for tumour survival and growth are affected. 
However, Banerji et al. (2008) found 17-AAG to be ineffective when administered to two 
melanoma patients with WT N-RAS/B-RAF (1-1.5 months to progression) compared to 
one with mutant N-RAS (and WT B-RAF; 49 months to progression) and another with 
mutant B-RAF (and WT N-RAS; 15 months to progression). In the same study, two other 
patients with mutant B-RAF (and WT N-RAS) only had 1.5-2 months of stabilised disease 
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before the tumour progressed. This study had a small number of test subjects and only 
one patient had mutant N-RAS which makes the results inconclusive. Nevertheless, data 
on a patient’s mutational status corresponding to Hsp90 inhibition will assist in the use of 
such inhibitors similar to the application of B-RAF (section 2.1.3) and KIT inhibitors 
(section 2.1.1) as discussed earlier.  
Montaqut et al. (2008) found that AZ628 (B-RAF inhibitor)-resistant melanoma cells had 
elevated levels of C-RAF that was responsible for the survival of these cells. Treatment 
with geldanamycin sensitised these cells to apoptosis by inhibiting Hsp90. This suggests 
that a combined application of RAF and Hsp90 inhibitors may improve treatment 
outcomes of melanoma patients. In a phase I clinical trial, the combination of sorafenib (B-
RAF inhibitor) and tanespimycin (17-AAG) showed clinical efficacy in four out of six 
melanoma patients (Vaishampayan et al., 2010). When 17-DMAG (Hsp90 inhibitor) was 
co-treated with imatinib mesylate (RTK inhibitor), a synergistic anti-proliferative effect 
was seen in uveal melanoma cells (WT B-RAF) (Babchia et al., 2008). Imatinib inhibits 
specific KIT mutations and secondary mutations have arised in imatinib-resistant tumours 
(Lim et al., 2008; Terheyden et al., 2010). Since KIT is a client protein of Hsp90, the 
inhibition of this heat shock protein may destabilise KIT irrespective of different receptor 
domain mutations thereby improving imatinib’s efficacy. On the whole, Hsp90 inhibitors 
would augment the effectiveness of other oncogenic protein (e.g. B-RAF, KIT) inhibitors 
in these patients. 
Gaspar et al. (2009) identified a possible mechanism of resistance which may occur in 
melanoma treated with 17-AAG. After continuous drug exposure, a 17-AAG-resistant 
melanoma cell line, WM266.4-RA6 was developed. This resistance was found to occur via 
downregulation of NAD(P)H/quinone oxidoreductase (NQO1) as ES936 (NQO1 inhibitor) 
reduced 17-AAG sensitivity in the non-resistant WM266.4 parental line. This suggests that 
17-AAG efficacy relies on NQO1 upregulation in these cells (Gaspar et al., 2009; Siegel et al., 
2011). Although, the same resistance occurred in glioblastoma cells, other structurally 
dissimilar Hsp90 inhibitors (VER-49009 and NVP-AUY922) were also shown to be effective 
(Gaspar et al., 2009). In another study, NVP-AUY922 inhibited proliferation in WM266.4 
(mutant B-RAF), SKMEL2 (mutant N-RAS; high NQO1) and SKMEL5 (mutant BRAF; low 
NQO1) melanoma cells in an NQO1-independent manner (Eccles et al., 2008). Although, the 
efficacy of its inhibiton in WT/mutant B-RAF or N-RAS is still ambiguous, Hsp90 has a 
broad spectrum of targets and its inhibition will affect multiple signalling pathways in 
tumours irrespective of their mutational status. Furthermore, Hsp90’s role in both the 
RAS/RAF/MEK and PI3K/AKT pathways which are common oncogenic pathways in 
melanoma makes it a promising target. Currently, some of these Hsp90 inhibitors are 
undergoing clinical trials.  
2.2.3 p38 MAPK and JNK 
Besides ERK, p38 MAPK and c-Jun NH2-terminal kinase (JNK) belong to the MAPK family 
(Muthusamy and Piva, 2010). UV-induced activation of p38 and JNK in normal skin cells 
were either pro- or anti-apoptotic depending on the cell type, UV type and dose used 
(Muthusamy and Piva, 2010). Unlike ERK, p38 and JNK pathways have not been frequently 
linked to melanoma incidences. However, there is evidence to suggest that these pathways 
may play a role in synergistic or additive effects together with chemotherapeutic agents to 
elicit cytotoxicity in melanoma cells (Keuling et al., 2010; Selimovic et al., 2008; Shieh et al., 
2010).   
www.intechopen.com
 
Skin Cancers – Risk Factors, Prevention and Therapy 
 
96
Melanoma cells resistant to ABT-737 die when they are co-treated with the p38 inhibitor, 
SB202190 (Keuling et al., 2010). The combination of ABT-737 and SB202190, enhanced 
caspase-dependent apoptosis in four melanoma cell lines harbouring different mutations. In 
contrast, the use of either SB203580 (p38 inhibitor) or SP600125 (JNK inhibitor) abolished 
Taxol-mediated apoptosis, ROS generation and decreased uncoupling protein 2 (UCP2) 
levels in A375 and BLM melanoma cells (Selimovic et al., 2008). Therefore, Taxol affects 
melanoma cells by upregulating these (p38 and JNK) pathways which in turn regulates the 
membrane potential, intracellular UCP2 and ROS levels. The JNK pathway was found to 
mediate doxycycline-induced cell death via ROS generation and apoptosis signal-regulating 
kinase 1 (ASK1) activation in A2058 melanoma cells (Shieh et al., 2010). Imatinib mesylate, a 
RTK inhibitor, mediated apoptosis and induced high levels of phospho-JNK and p38 in 
B16F0 melanoma cells (Chang et al., 2011). In this study, SP600125 was shown to enhance 
apoptosis in the imatinib mesylate-treated melanoma cells.    
p38 was implicated in aiding melanoma transendothelial migration in co-cultures with 
human vascular endothelial cells (HUVEC) (Khanna et al., 2010). When A2058 melanoma 
cells were co-cultured with HUVEC, the latter’s vascular endothelial (VE)-cadherin 
junctions were disrupted and gap formations occurred allowing migration of melanoma 
cells. Neutralisation of soluble factors (IL8, IL1ǃ) released from A2058 melanoma cells 
abrogated the p38 pathway in HUVEC and prevented VE-cadherin disassembly and gap 
formation which was also affirmed by the inhibition of p38 in these cells. In contrast, 
downregulation of Ras association domain family 1, isoform A (RASSF1A)/ASK1/p38 in 
part, was involved in melanoma development. RASSF1A levels were lower in melanoma 
tissues compared to benign and normal melanocytes (Yi et al., 2011). Expression of 
RASSF1A in RASSF1A-deficient A375 melanoma cells induced an anti-proliferative and  
pro-apoptotic effect which coincided with decreased tumorigenic potential of these cells as 
well as an increase in ASK1 and p38 levels.   
Collectively, the roles of p38 and JNK in melanoma development, apoptosis or 
chemoresistance needs to be tested on a case by case basis as it seems to vary with different 
cytotoxic agents and cell types. Forced expression of active p38/JNK or its inhibition may be 
useful in enhancing the efficacy of chemotherapeutic agents in inducing apoptosis in 
tumour cells. In order to prevent disruption of normal cellular homeostasis, it is imperative 
to identify melanoma-specific treatment vehicles. 
2.2.4 Phosphatases 
Phosphatases regulate cell signal transduction by dephosphorylating phospho-proteins 
resulting in either their activation or deactivation (Bermudez et al., 2010; Haagenson and 
Wu, 2010). Protein tyrosine phosphatases (PTP) and serine/threonine phosphatases (S/TP) 
dephosphorylate tyrosine and serine/threonine residues, respectively (Hamilton and 
Bernhard, 2009). Phosphatases in the nucleus are involved in controlling cell cycle 
progression and other nuclear processes (Bollen and Beullens, 2002). The MAPK signalling 
pathway has several MAPK phosphatases (MKP) regulating the activity of each kinase. The 
dual specificity phosphatases (DSP) target MAPK at both tyrosine and threonine residues 
(Bermudez et al., 2010). In some human cancers, these phosphatases are either 
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PTEN is a phosphatase that removes phospho-groups in both lipids and proteins (Hamilton 
and Bernhard, 2009), and is deleted/inactivated in some melanomas (Paraiso et al., 2011). 
PTEN dephosphorylates AKT and inhibits cell survival and its loss enables melanoma cells 
to overcome B-RAF inhibition via the AKT survival pathway (Paraiso et al., 2011). In 
PLX4720 (B-RAF inhibitor)-treated PTEN+/+ melanoma cells, AKT signalling was inhibited 
and Bim-mediated apoptosis was enhanced compared to PTEN-/- cells (Paraiso et al., 2011). 
Stewart et al. (2002) found no mutations in PTEN coding regions but the protein levels were 
low or undetectable in five melanoma cell lines (WM35, WM134, A375, A375-S2, MeWo). 
When PTEN adenoviral vectors (Ad-PTEN) were transfected into these cells, there was an 
increase in AKT dephosphorylation, apoptosis and growth inhibtion. A decrease in cell 
migration/invasive property and a corresponding increase in E-cadherin levels were also 
observed. These data emphasise the role PTEN phosphatase plays in melanoma.  
Chen et al. (2010) found that high levels of phospho-myristoylated alanine-rich C-kinase 
substrates (MARCKS) and their upstream activator, protein kinase Cǂ (PKC) were responsible 
for metastasis of B16F10 melanoma cells. In weakly motile F1 melanoma cells, phospho-
MARCKS were undetectable but PKC levels were still high which suggests that an inhibitory 
mechanism exists to maintain low phospho-MARCKS levels in these cells. When the F1 cells 
were treated with okadaic acid (protein phosphatase inhibitor; inhibits PP1 and 2A) the 
phosphorylation of MARCKS increased while the addition of a PKC inhibitor abolished these 
levels (Chen and Rotenberg, 2010; Clarke et al., 1993). This study suggests that there is a ratio 
between PKC and protein phosphatase levels which determines the amount of phospho-
MARCKS present in these cells and this may affect their motility. Therefore, it is possible that 
in metatstatic melanoma cells, high levels of protein kinases may override the effect of protein 
phosphatases or these phosphatases may be either suppressed or lost.  
McArdle et al. (2003) observed that advanced melanoma had greater phosphotyrosine 
residues than did early stage lesions. Microarray analysis of metastatic melanoma cell lines 
(WM9, WM39, WM852) showed a 32% difference in total phosphatase gene expression 
compared to normal melanocytes. In some of these cells, DSP, PTP, S/TP and acid/alkaline 
phosphatases were downregulated when compared to naevus and melanocytes (McArdle et 
al., 2005). Of the DSP identified, DSP10 (MKP5) was lower in all three melanoma cell lines 
tested while DSP5 expression was decreased. DSP10 is a cytoplasmic and nuclear 
phosphatase which dephosphorylates p38 and JNK while DSP5 is localised to the nucleus 
and inactivates ERK (Bermudez et al., 2010). It was speculated that since DSP10 maps to 
chromosome 10q25, it might be downregulated/deleted as it is in the same region as PTEN 
(chromosome 10q23.3) which is often lost in some melanomas (McArdle et al., 2005). The 
low levels of PTP in conjunction with amplified phosphotyrosine levels may prevent 
inactivation of crucial kinases that drives melanoma metastasis.  
In contrast, some melanoma cell lines have higher total PTP activity than do melanocytes. 
Since, only total PTP was measured irrespective of subcellular localisation, type and 
function, it is possible that those which were upregulated may be pro-tumorigenic. Sun et al. 
(2011) found that the PP1 catalytic subunit ǃ isoform was significantly overexpressed in 
human melanoma compared to nevi samples. DSP4 (MKP2) which dephosphorylates 
MAPK was found to be upregulated in melanoma cell lines (Teutschbein et al., 2010). It is 
possible that their increase could compensate for the high levels of ERK produced in these 
cells. Laurent et al. (2011) found that overexpression of PTP4A3 in uveal melanoma cell lines 
correlated to a high degree of cell migration and invasisveness in vivo. Another phosphatase, 
PP2A was involved in tumour cell migration as its inhibition by cytostatin upregulated 
those cytokines involved in augmenting natural killer cell levels and activity in vivo which 
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resulted in reduced mice B16 melanoma pulmonary metastasis (Kawada et al., 2003). In 
another study, MKP1 (DSP1) expression was found to be higher in melanoma tissue samples 
(~six-fold) than in melanocytes (Kundu et al., 2010). Tyrosine phosphatase inhibitor-3 
inhibited MKP1 activity and had a synergistic effect with interferon ǂ2b to inhibit WM9 
melanoma cell growth (Kundu et al., 2010). MKP1 has been associated with chemoresistance 
in other human cancers (lung and breast cancer) but it is not known if the same occurs in 
melanoma (Haagenson and Wu, 2010).  
Tang et al. (1999) observed a greater expression of cyclin-dependent kinase 2 (CDK), CDK6 
and CDC25A in metastatic melanomas than in benign nevi. CDC25A is a tyrosine 
phosphatase that dephosphorylates/activates CDK, allowing entry into the cell cycle and as 
such may be involved in melanoma proliferation (Tang et al., 1999).  Koma et al. (2004) 
found that deltagamma 1 (ΔǄ1) (truncated variant of PP2A B65Ǆ regulatory subunit) confers 
radioresistance to metastatic melanoma cells. When F10 cells were transfected with ΔǄ1, 
there was a decrease in radiation-induced p53 protein levels, BAX transactivation and 
apoptosis in vivo. This is due to ΔǄ1-mediated dephosphorylation of MDM2 which targets 
p53 for degradation and as a result prevents the production of p53-inducible apoptotic 
factors. It is conceivable that the transition from benign to metastatic melanoma may also be 
aided by progressive mutations occurring in these phosphatases. 
Although, microarray and global gene expression data is useful to elucidate those 
phosphatases regulated in melanoma, there seems to be a lack of functional studies 
conducted in these tumours. Data on the mutational status of phosphatases in melanoma is 
limited.  Nevertheless, the existing data creates a compelling argument that these proteases 
may prove to be a valuable tool in targeting phospho-proteins that regulate pro-tumour 
activities in these cells. As phosphatase inhibitors can promote tumour activity, it is 
necessary to delineate the specific roles played by these phosphatases in melanoma (Fujiki 
and Suganuma, 2009).  
3. Conclusion 
On the whole, it has been shown from numerous studies that melanomas cannot be treated 
using a single agent. This is partly due to the presence of melanoma subgroups harbouring 
one or more mutations; KIT only, N-RAS only, B-RAF only, KIT and N-RAS, and KIT and  
B-RAF mutant melanomas (Curtin et al., 2006). In addition, a cocktail of inhibitors and new 
therapeutical targets are necessary to prevent drug resistance due to activation of 
alternative/compensatory signalling. Although, joint therapies have recently been 
suggested, a cocktail of drugs may induce systemic toxicities and other anomalies, and as 
such requires more pre-clinical studies on effective dosages. In conclusion, the  
RAS-RAF-MEK pathway still remains a promising target for therapy but the identification 
of new molecular targets might enhance the efficacy of existing treatments. This would 
allow for melanoma therapy to ‘strike from all angles’ in terms of oncogenic mutations, 
survival pathways, metastasis and angiogenesis.  
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